// App-Quantinova.ai

: First Generation PI3KC2α Inhibitors are Potently Anti‐Thrombotic and Improve on the Safety Profile of Current Anti‐Platelet Therapies

Researchers

Presenter

  • M. Moon

Principal Investigators

  • M. Selvadurai

  • S. Mountford

  • R. Brazilek

  • J.-Y. Rinckel

  • A. Eckly

  • C. Gachet

  • W. Nesbitt

  • P. Thompson

  • J. Hamilton

Medical Centers

  • Monash University, Australian Centre for Blood Diseases, Melbourne, Australia

  • Monash University, Medicinal Chemistry, Melbourne, Australia

  • Universite de Strasbourg, Strasbourg, France

  • RMIT University, Microplatforms research group, Melbourne, Australia

Locations

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved